Biotech News

AtriCure to Announce Second Quarter 2026 Financial Results

AtriCure (ATRC)AtriCureEarnings

MASON, Ohio --(BUSINESS WIRE)--Jul. 2, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter

Related news

AtriCure

Atrial Fibrillation Surgery AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm. Ablation Technologies The Isolator Synergy Ablation...

Recent company news

Stock data

Close
39.49 USD
Market cap
1.31B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States